Currently, antibodies raised against PD1/PDL1and CTLA4 are licensed for use in clinical practice.2 PD1 is highly expressed on activated T cells and interactswith its ligands, PDL1 and PDL2, expressed on antigen-presenting cells,inflamed tissue, and some cancer cells; the outcome of this interactionis suppression of T cell activity. This evidence concerns the gene CD274 and cancer.